An Understanding of Mechanism-Based Approaches for 1,3,4-Oxadiazole Scaffolds as Cytotoxic Agents and Enzyme Inhibitors - Review

Sep 24, 2026

Cancer drives major morbidity and mortality worldwide, motivating continual search for new anticancer therapeutics. This review focuses on the 1,3,4-oxadiazole scaffold, highlighted for diverse biological activities and its relevance to cancer treatment. Structural modification of 1,3,4-oxadiazole derivatives is emphasized to achieve high cytotoxicity against malignant cells, including strategies that enhance selective interactions with nucleic acids, enzymes, and globular proteins. The work synthesizes findings on molecular docking and SAR, detailing antiproliferative mechanisms via inhibition of key targets such as telomerase, HDAC, thymidylate synthase, and thymidine phosphorylase.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages42

Reading Time1 h 46 min

AccessFree to download

Introduction

Cancer as a Public Health Challenge

1,3,4-Oxadiazole Scaffold in Anticancer Research

pharmaceuticals Review An Understanding of Mechanism-Based Approaches for 1,3,4-Oxadiazole Scaffolds as Cytotoxic Agents and Enzyme Inhibitors Davinder Kumar 1, Navidha Aggarwal 2, Aakash Deep 3, Harsh Kumar 1, Hitesh Chopra 4, Rakesh Kumar Marwaha 1, * and Simona Cavalu 5 Citation: Kumar, D.; Aggarwal, N.; Deep, A.; Kumar, H.; Chopra, H.; Marwaha, R.K.; Cavalu, S. An Understanding of Mechanism-Based Approaches for 1,3,4-Oxadiazole Scaffolds as Cytotoxic Agents and Enzyme Inhibitors. Pharmaceuticals 2023, 16, 254. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ph16020254](10.3390/ph16020254) Academic Editors: Parvesh Singhand Vipan Kumar Received: 29 December 2022 Revised: 30 January 2023 Accepted: 2 February 2023 Published: 7 February 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, India 2 MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala 133207, India 3 Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani 127021, India 4 Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, India 5 Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania * Correspondence: [rkmarwaha.mdu@gmail.com](rkmarwaha.mdu@gmail.com) Abstract: The world's health system is plagued by cancer and a worldwide effort is underway to ﬁnd new drugs to treat cancer. There has been a signiﬁcant improvement in understanding the pathogenesis of cancer, but it remains one of the leading causes of death. The imperative 1,3,4-oxadiazole scaffold possesses a wide variety of biological activities, particularly for cancer treatment. In the development of novel 1,3,4-oxadiazole-based drugs, structural modiﬁcations are important to ensure high cytotoxicity towards malignant cells. These structural modiﬁcation strategies have shown promising results when combined with outstanding oxadiazole scaffolds, which selectively interact with nucleic acids, enzymes, and globular proteins. A variety of mechanisms, such as the inhibition of growth factors, enzymes, and kinases, contribute to their antiproliferative effects. The activity of different 1,3,4-oxadiazole conjugates were tested on the different cell lines of different types of cancer. It is demonstrated that 1,3,4-oxadiazole hybridization with other anticancer pharmacophores have different mechanisms of action by targeting various enzymes (thymidylate synthase, HDAC, topoisomerase II, telomerase, thymidine phosphorylase) and many of the proteins that contribute to cancer cell proliferation. The focus of this review is to highlight the anticancer potential, molecular docking, and SAR studies of 1,3,4-oxadiazole derivatives by inhibiting speciﬁc cancer biological targets, such as inhibiting telomerase activity, HDAC, thymidylate synthase, and the thymidine phosphorylase enzyme. The purpose of this review is to summarize recent developments and discoveries in the ﬁeld of anticancer drugs using 1,3,4-oxadiazoles. Keywords: 1,3,4-oxadiazole; synthesis; telomerase; HDAC; thymidylate synthase; anticancer potential 1. Introduction Humankind faces one of the most challenging of public health challenges, in the form of cancer. The development of cancer involves the uncontrollable division of abnormal cells that can inﬁltrate and destroy normal tissues in the body. High morbidity and mortality rates characterize the disease; after cardiovascular disease, it is the second leading cause of death in many countries. In order to reduce cancer death rates worldwide, che

FAQs

Why is the 1,3,4-oxadiazole scaffold important in anticancer drug development?

It shows a wide range of biological activities, with particular relevance to cancer treatment and cytotoxic effects against malignant cells.

Which molecular targets are highlighted for 1,3,4-oxadiazole derivatives?

The review emphasizes mechanisms involving inhibition of telomerase activity, HDAC, thymidylate synthase, thymidine phosphorylase, and other cancer-relevant enzymes and proteins.

How do structural modifications contribute to anticancer potency?

Structural changes are used to improve cytotoxicity and to promote selective interactions with nucleic acids, enzymes, and globular proteins, leading to antiproliferative effects.

Sep 24, 2026

Uploaded by pixelkiddo